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ABSTRACT 
The compound cribrostatin 6, isolated in 2003 from the blue colored marine sponge 
Cribrochalina  sp., has been found to exhibit both potent antimicrobial activity, as well as 
antineoplastic activity, making it of interest for its biological functionalities, as well as its unique 
tricyclic imidazo[5,1-a]isoquinolinedione structure. Using recently established methodology by 
Knueppel and Martin, known to be the shortest reported sequence of steps to synthesize this 
compound, analogs of cribrostatin 6 can be designed and synthesized to potentially find more 
biologically effective analogues, which can also be tested for antimicrobial and antineoplastic 















In a note written in 1828 from the German chemist Friedrich Wöhler to his mentor Jöns 
Jacob Berzelius, Wöhler proclaimed “I must tell you that I can make urea without the use of 
kidneys, either man or dog. Ammonium cyanate is urea,” and thus from his discovery, the field 
of natural product [organic] synthesis was born.
1
 Up until the mid-18
th
 century, scientists 
believed mostly in a widespread belief called “vitalism” which maintained that organic 
compounds could be modified by chemistry but could only be produced through the agency of a 
vital force present in living plans and animals. The term “organic” had not been used even until 
1807 when Berzelius suggested its use to distinguish between compounds devised from living 
(organic) and nonliving (inorganic) matter. When Wöhler synthesized urea, an organic 
compound, from the inorganic substances, lead cyanate and ammonium hydroxide (Scheme 1), 
scientists began to realize that organic compounds could arise from sources other than live plants 
and animals.  
 








 The theory of vitalism eroded as synthetic chemists began producing organic compounds 
in the lab over the next two decades that followed. Hermann Kolbe’s synthesis of acetic acid in 
1844 and Marcellin Berthelot’s prolific work, which produced many organic compounds, such as 
methane and acetylene in 1850, marked the end of the vitalism theory and ever since then, 
organic chemists have not looked back.  
 
 Of the many significant awards that have been bestowed upon chemists, The Nobel Prize 
in Chemistry and the Wolf Prize in Chemistry both have been awarded to many chemists for 
their work in the field of or contributions to natural product synthesis. Bookended currently by E. 
Fischer’s Nobel Prize in 1902 for his work on sugar and purine synthesis as the earliest synthetic 
award and R. Grubbs’s Nobel Prize in 2005 for the development of the metathesis method in 
organic synthesis, the field continues to grow, even as we approach the 200-year anniversary of 
the birth of the field.  
 Chemists continue to pursue the field of natural product synthesis for the many 
challenges and rewards it offers. K.C. Nicolaou aptly commented that “There are many reasons 
why natural product synthesis withstood the test of time as an enabling and rewarding science 
and technology, not to mention its attractiveness as an intellectual and creative endeavor offering 
opportunities for discovery and invention.”
2
 These reasons include taking on the challenge 
presented by certain molecular architectures in order to discover and invent new synthetic 
strategies and methods, finding a route to synthesizing a natural product in larger quantities for 
exploration of its biological activity and applications, applying a unique set of strategies and 
methods to alter the structure of a natural product in an effort to enhance its selectivity and 
biological potency, confirming  and characterizing natural products in the literature, and 
attempting to synthesize monumental natural products simply for the sake of synthesis.  
 My thesis work ties together a couple of these reasons in a project that looks to utilize the 
intriguing molecular architecture of cribrostatin 6 and explore the biological activity of analogs  





As antibiotic-resistant Gram-positive bacteria becomes a bigger threat to society because 
of their increasing resistance to multiple drugs, the need for new structural classes of antibiotics 
continues to increase. Cribrostatin 6 (Figure 1) is one of a number of natural product compounds 
isolated from the blue marine sponge Cribrochalina sp.  
 








Isolated in 2003 by Pettit et al.
3
, cribrostatin 6 (1) is a dark blue cancer cell growth 
inhibitor of both murine P388 lymphocytic leukemia and human cancer cell lines. In addition to 
this broad anticancer activity, cribrostatin 6 also exhibits antimicrobial potency against a number 
of antibiotic-resistant Gram-positive bacteria and pathogenic fungi, with the most efficacy 
against Streptococcus pneumoniae, the most common bacterial cause of bacterial meningitis. 
There has been interest in synthesizing cribrostatin 6, due in part to its interesting 
biological activity, but also because of its unique tricyclic imidazo[5,1-a]isoquinolinedione 
structure. Both the Nakahara
4
 (Scheme 2) and Kelly
5
 (Scheme 3) groups have devised syntheses 
of cribrostatin 6 before, but the novel total synthesis by Knueppel and Martin
6
 (Scheme 4) is less 






















































Results and Discussion 
The goal of this project was to synthesize new analogs of cribrostatin 6 for biological 
testing using the synthetic route pioneered by Daniel Knueppel as a template for assembling 
together the starting materials. From an ease of accessibility standpoint, the n-butyl/ethoxy 
analog (Figure 2) was the first compound pursued because of the high similarity between the 













An n-butyl/ethoxy squarate derivative (5) was prepared as shown in Scheme 5, using the 
same approach that was used to obtain the methyl/ethoxy squarate used in Daniel’s natural 
product synthesis.  
 
















3 4 5  
 
The starting material for this reaction was synthesized following a literature procedure 
calling for squaric acid to be converted into diethyl squarate (3)
7
, and then the addition of n-butyl 
lithium to the 3, gave the alkoxide (4), which was then treated with TFAA to obtain the desired 
n-butyl/ethoxy squarate (5).  
The linear forward synthesis used was the same used for cribrostatin 6; upon bringing up 
enough of the necessary alkyne XX, the key intermediate XX was generated by coupling the 
alkyne XX with the n-butyl/ethoxy squarate derivative used in place of the methyl/ethoxy 




Scheme 6: Synthesis of key intermediate 7 
NN
i. n-BuLi,  THF, -78 °C
ii. n-Butyl squarate 5, THF,











 Multiple attempts to generate the key intermediate (7) were necessary; azeotroping the 
alkyne (5) with benzene helped eliminate all water from the reaction and was perhaps the best 
approach to obtaining the key intermediate. Despite the low 33% yield of key intermediate (7), 
123mg was enough to push forward to obtain analog 2.  
 
Scheme 7: Completion of the synthesis of the n-butyl/ethoxy cribrostatin 6 analog 
CH3CN, 130 °C 
(40 mins)


















7 8 2  
 
Using the one-pot procedure designed for the cribrostatin 6 synthesis, the key 
intermediate 7 was heated alone in acetonitrile under argon for 40 minutes to form the 
hydroquinone 8 (Scheme 7), as indicated by a color change from peach to dark brown/amber. A 
majority of the solvent was then evaporated before Pd/C was added to the hydroquinone, and the 
reaction was left to stir overnight with a reflux condenser while open to air, to aid in oxidation, to 
yield the n-butyl/ethoxy cribrostatin 6 analog (2).  
 Upon workup, the cribrostatin 6 analog 2 was obtained as a dark navy blue solid in 11.4% 
yield from 7. On the TLC plate the analog was easily identified by a blue spot, a trademark 
 
similar to that of cribrostatin 6. Analog 2 was characterized and then sent to the Hergenrother 
group for biological activity testing.  
 Results obtained from the Hergenrother group revealed that analog 2 was not anywhere 
near being significantly more effective than cribrostatin 6  against the two cell lines tested (HL-
60, leukemia; U-937, lymphoma). Based on the currently known information about the 
cribrostatin 6 mode of action, a suggested focus/idea for the synthesis of more effective 
compounds was to focus on synthesizing cribrostatin 6 analogs that would be more easily 
bioreduced, most likely by cytochrome p450s, in the cell. Because bioreduction correlates with 
electrochemical reduction potentials, the focus was shifted toward designing compounds with 
higher [more positive] electron reduction potentials. This led to the current pursuit of analogs 9 
and 10, as shown in Scheme 8. 
 























































In summary, using the synthetic route devised by Knueppel and Martin as a template, a 
new cribrostatin 6 analog was produced and submitted for biological activity testing. Based upon 
preliminary results obtained, new analogs were identified as being potentially more effective 
candidates and work is ongoing to synthesize those analogs in the lab. 
 Ideally, future work on this project would be centered around synthesizing analogs 9  and 
10 with higher reduction potentials and testing them for biological activity while also measuring 
their chemical reduction potentials in order to find whether or not a correlation of cytotoxicity 
and reduction potential exists. 
 
 
General Methods  
General Methods. Solvents and reagents were reagent grade and used without purification 
unless otherwise specified. THF was passed through two columns of neutral alumina. CH3CN 
was passed through two columns of molecular sieves. Reactions involving air- or moisture-
sensitive reagents or intermediates were performed under an inert atmosphere of argon or 
nitrogen in glassware that had been oven dried. 
1
H and NMR spectra were obtained as solutions 
in CDCl3, and chemical shifts are reported in parts per million (ppm) in reference to CDCl3 (7.24 
ppm). Coupling constants are reported in hertz (Hz). Spectral splitting patterns are designated as  
follows: s, singlet; d, doublet; t, triplet; q, quartet; app, apparent; br, broad; m, multiplet; comp, 
complex multiplet. All products that were used without further purification were >95% pure by 
1








3-butyl-4-ethoxycyclobut-3-ene-1,2-dione (5) (1vc41).  A solution of n-BuLi (3.34 mL, 2.6 M, 
8.82 mmol) in hexanes was added dropwise to a solution diethyl squarate (1.5 g, 8.82 mmol) in 
THF (20 mL) at –78 °C. After 10 minutes, the solution was quenched with trifluoroacetic 
anhydride (1.47 mL, 10.58 mmol) and 15 mL of 10% aqueous NH4Cl, whereupon it was cooled 
to room temperature. The mixture was extracted with Et2O/5% aqueous NaHCO3 (1:1) (3 × 10 
mL each). The aqueous layers were washed with Et2O (2 x 5 mL). The combined organic phases 
were dried (Na2SO4), and the solvent was removed under reduced pressure. The residue was 
purified by flash column chromatography eluting with EtOAc/CH3Cl (1:3) to give 0.91 g (57%) 
of 5 as a white solid; 
1
H NMR (400 MHz, CDCl3) δ 4.78 (m, 2 H), 2.59 (m, 2 H), 1.68 (m, 2 H), 




1-(but-3-ynyl)-2-methyl-1H-imidazole (6) (1vc25). 2-Methylimidazole (4.58 g, 55.74 mmol) 
was added to a solution of but-3-ynyl 4-methylbenzenesulfonate (2.5 g, 11.15 mmol) in CH3CN 
(15.5 mL). The reaction was heated for 18 h at 70 °C, whereupon it was cooled to room 
temperature, and the solvent was removed under reduced pressure. The residue was purified by 
flash column chromatography eluting with CHCl3/MeOH (10:1) to give 0.81 g (54%) of 34 as a 
clear oil; 
1
H NMR (400 MHz, CDCl3) δ 6.85 (d, J = 1.2 Hz, 1 H), 6.82 (d, J = 1.2 Hz, 1 H), 3.95 





(7) (1vc44). A solution of n-BuLi (0.55 mL, 2.6 M, 1.42 mmol) in hexanes was added dropwise 
to a solution of 6 (158 mg, 1.18 mmol) in THF (5.9 mL) at –78 °C. After 35 min at –78 °C, a 
solution of 3-butyl-4-ethoxycyclobut-3-ene-1,2-dione (5) (323 mg, 1.77 mmol) in THF (5 mL) at 
–78 °C was added dropwise via cannula. After 15 min at –78 °C, stirring was continued for 1.5 h 
at 0 °C. Saturated aqueous NH4Cl (5 mL) and brine (5 mL) were added, and the mixture was  
extracted with EtOAc (3 × 10 mL). The combined organic phases were dried (Na2SO4), and the 
solvent was removed under reduced pressure. The residue was purified by flash column 











8-butyl-9-ethoxy-3-methylimidazo[5,1-a]isoquinoline-7,10-dione (2) (1vc45). A solution of 7 
(124 mg, 0.40 mmol) in CH3CN (300 mL) was heated at reflux for 40 min in a preheated oil bath 
(130 °C). After cooling to room temperature, the solution was concentrated to approximately 5 
mL by evaporation under reduced pressure. Pd/C (17 mg, 10 wt. % loading) was added along 
with 12 mL CH3CN and approximately 1 mL MeOH, and the reaction was heated for 18 h at 80 
°C. After cooling to room temperature, the solvent was removed under reduced pressure, and the 
 
residue was purified by flash column chromatography eluting with CHCl3/MeOH (10:1) to give 
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